Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21209086 | 0.90 | MEN1 (0.47) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL27243556 | 0.87 | TDP1 (0.56) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL27243560 | 0.87 | TDP1 (0.56) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1105702 | 0.84 | PCSK9 (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL27685460 | 0.83 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL26151120 | 0.83 | TDP1 (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL24117848 | 0.83 | TDP1 (0.59) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL9220420 | 0.82 | MEN1 (0.46) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL17019827 | 0.82 | MEN1 (0.46) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL19628801 | 0.82 | MEN1 (0.46) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104619698-B | Pyrrolidin derivatives and the purposes as complement pathway regulator thereof | 诺华股份有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CTSK 385/4885CTSS 340/4885MEN1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.